Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping

A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in relapsed lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition

First Line Ipilimumab+Nivolumab Combined with two cycles of Chemotherapy in NSCLC [FINN]

An open-Label, multi-Center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued Treatment with ceritinib

Multicenter Study to Evaluate the Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic Non-squamous NSCLC or Extensive-stage SCLC Under First-line Treatment With Atezolizumab and Platinum-based Chemotherapy

A phase II trial to evaluate efficacy and safety of erdafitinib in patients with advanced squamous NSCLC (sqNSCLC) harboring FGFR genetic alterations after relapse of standard therapy

A Multicenter, Open-label, Dose-escalating, Phase I Trial with GEM3PSCA, a PSCA Targeted Bispecific Antibody Engaging T-cells, in Patients with Progressive Disease after Standard Systemic Therapy in Cancers with Positive PSCA Marker

NIS zur Beobachtung von Wirkungseffekten von Atezolizumab in der alltäglichen Routine bei Patienten mit lokal fortgeschrittenem oder metastasiertem nicht kleinzelligem Lungencarcinom nach vorheriger Chemotherapie